Paroxetine Mesylate (Brisdelle)

About

Paroxetine mesylate is a selective serotonin reuptake inhibitor (SSRI) specifically FDA-approved for the treatment of moderate to severe vasomotor symptoms (hot flashes) associated with menopause. It is the first non-hormonal option approved for this indication.

Efficacy

Reduces frequency of moderate-to-severe hot flashes by 33-43% compared to placebo at 12 weeks; reduces severity of hot flashes compared to placebo

Targets Symptoms